Gemcitabine Pancreatic Cancer
Nov. 28, 2024
Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer: Molecular Therapy - Nucleic Acids Mechanisms Underlying Gemcitabine Resistance in Pancreatic Cancer and Sensitisation by the iMiD™ Lenalidomide | Anticancer Research LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes | Molecular Cancer | Full Text Gemcitabine Pancreatic Cancer
![PDF] Erlotinib plus gemcitabine compared with gemcitabine alone in patients with ad…](https://d3i71xaburhd42.cloudfront.net/1a6ab5ded3face432eed101b9a694517562403bb/4-Figure1-1.png){kind=link}
![GABRP promotes CD44s-mediated gemcitabine resistance in pancreatic cancer [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2022/12728/1/fig-2-2x.jpg){kind=link}
![PDF] Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activ…](https://d3i71xaburhd42.cloudfront.net/fe4dc2f7c9f1430d6649ec2b8aef8c76c4ddc4ef/7-Figure3-1.png){kind=link}
![PDF] Pancreatic Cancer Chemoresistance to Gemcitabine | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e6237c2d538c2280a1a87b9df06adc1a9e204e63/12-Figure3-1.png){kind=link}
